BTG3 and chronic lung allograft dysfunction: During the follow-up period, there were no differences in late post-LT complications between the two groups either; however, a non-significant trend towards lower prevalence of chronic lung allograft dysfunction (CLAD) was observed in patients who became ANA-negative (29% vs. 54%).